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ABSTRACT
Surgical resection is a standard component of treatment in the clinical 
management of patients with glioblastoma multiforme (GBM). However, experimental 
therapies are rarely investigated in the context of tumor debulking in preclinical 
models. Here, a surgical debulking GBM xenograft model was developed in nude rats, 
and was used in combination with CD47 blocking immunotherapy, a novel treatment 
strategy that triggers phagocytosis of tumor cells by macrophages in diverse cancer 
types including GBM. Orthotopic patient–derived xenograft tumors expressing CD47 
were resected at 4 weeks after implantation and immediately thereafter treated with 
anti-CD47 or control antibodies injected into the cavity. Debulking prolonged survival 
(median survival, 68.5 vs 42.5 days, debulking and non-debulking survival times, 
respectively; n = 6 animals/group; P = 0.0005). Survival was further improved in 
animals that underwent combination treatment with anti-CD47 mAbs (median survival, 
81.5 days vs 69 days, debulking + anti-CD47 vs debulking + control IgG, respectively; 
P = 0.0007). Immunohistochemistical staining of tumor sections revealed an increase 
in recruitment of cells positive for CD68, a marker for macrophages/immune cell types, 
to the surgical site (50% vs 10%, debulking vs non-debulking, respectively). Finally, 
analysis of tumor protein lysates on antibody microarrays demonstrated an increase 
in pro-inflammatory cytokines, such as CXCL10, and a decrease in angiogenic proteins 
in debulking + anti-CD47 vs non-debulking + IgG tumors. The results indicated that 
surgical resection combined with anti-CD47 blocking immunotherapy promoted 
an inflammatory response and prolonged survival in animals, and is therefore an 
attractive strategy for clinical translation.




Prognosis of glioblastoma multiforme (GBM) 
remains bleak, with a median survival of about 14.6 
months and only 4% of patients surviving 5 years after the 
initial diagnosis [1–3]. Surgical resection is considered to 
be the most effective approach in the treatment of GBM 
patients [4–7]. Radio- and chemotherapy are also generally 
applied in combination with surgery to treat GBM in 
the clinic. Despite this multimodal treatment regimen, 
most GBM cases relapse within one year, and almost all 
relapses occur at the tumor debulking site. The failure 
of standardized therapies is believed to be a result of 
cellular and genetic inter- and intra-tumor heterogeneity, 
infiltration deep into the surrounding parenchyma, and 
a dysfunctional blood vessel supply which is unable to 
effectively deliver drugs to the tumor bed [8–11].
Immunotherapy is fast becoming a viable strategy 
for the treatment of a variety of highly aggressive human 
solid tumor types. The approach exploits the expression of 
tumor specific proteins and thus succeeds at eliminating 
tumor cells while sparing normal cells. A novel target for 
immunotherapy is CD47, a cell surface protein that is often 
highly expressed on human tumors and enables escape 
from immune surveillance. It is a cell transmembrane 
protein, also known as an integrin associated protein 
that belongs to the immunoglobulin superfamily [15]. 
CD47 functions as a ligand of signal regulatory protein-α 
(SIRPα), an inhibitory protein expressed on macrophages 
[16]. This interaction, also known as a “don’t eat me” 
signal, protects cells from phagocytosis through a 
signaling cascade transmitted via phosphorylation of the 
immunoreceptor tyrosine-based inhibition motif present 
on the cytoplasmic tail of SIRPα [17]. Studies performed 
with experimental models of solid tumors including GBM 
as well as some hematopoietic cancers have shown that 
blocking the interaction between CD47 and SIRPα with 
anti-CD47 monoclonal antibodies (mAbs) promotes 
phagocytosis in vitro and inhibits tumor growth in vivo 
[18–23]. One of the caveats in these models, particularly 
in the case of GBM, is that antibody is administered to 
the experimental animals at an early stage in tumor 
development. Therefore, it remains unclear as to whether 
the antibody is effective on mature or recurrent tumors as 
is the status for GBM patients at diagnosis.
In this study, we sought to refine the strategies to 
evaluate the feasibility of targeting CD47 therapeutically 
in a clinically relevant model of GBM. We developed a 
protocol for surgical resection of GBM in nude rats which 
parallels the clinical course observed in human patients, 
tumor debulking followed by tumor relapse, and the model 
was used specifically to test combination therapy with 
anti-CD47 mAb. The results indicate that CD47 blocking 
immunotherapy might be a promising postsurgical treatment 
for GBM and that targeting CD47 has the potential to 
eliminate tumor cells driving recurrence in GBM.
RESULTS
Surgical debulking of GBM xenografts at 4 
weeks post-implantation enhances survival
Surgical debulking is a standard treatment for patients 
with GBM. To further understand the characteristics and 
cycles of GBM growth, resection and tumor recurrence 
in the clinic, a novel surgical debulking model using a 
GBM xenograft (P3) was developed. P3 spheroids (n = 5; 
300 – 400 μm in diameter) were selected from culture and 
implanted in nude rats (Figure 1A). Survival time (days) 
was calculated on the basis that the day of implantation 
was day 1. MRI scans were performed to monitor tumor 
growth as well as debulking and recurrence (Figure 1B). 
At ~ 4 weeks following implantation, surgical resection 
was performed. PET scanning confirmed nearly complete 
debulking of the tumor (Figure 1B, middle panel), but also 
revealed that tumor cells remained within the resected 
margin. Thus, tumors still recurred within ~ 4 weeks of 
tumor debulking (Figure 1B, lower panel).
Growth curves as assessed by tumor volume on MRI 
between non-debulking and recurrent tumors differed (P 
= 0.001), indicating that surgery was in fact beneficial 
(Figure 1C). All rats survived to the end of the study with 
tumor debulking significantly prolonging overall survival 
time as assessed in survival curves (median survival, 68.5 
vs 42.5 days, debulking and non-debulking survival times, 
respectively; Figure 1D).
Vascular morphology and increased proliferation 
distinguish resected from non-resected 
xenografts
To address mechanisms underlying xenograft growth 
following surgery, vascular morphology and proliferation, 
hallmark pathological features of GBM, were examined 
in debulking and non-debulking xenografts. Morphology 
of the vasculature in xenografts was evaluated by 
immunohistochemical staining for vWf revealing vessels 
with a small diameter/lumen in non-debulking tumors. In 
contrast, vessels with larger lumen diameters were found in 
debulking tumors (Figure 2A). Quantification of the vessel 
area fraction based on vWF staining revealed that vessel 
area in debulking tumors was significantly greater than in 
non-debulking tumors (6.5% vs 3.5%, debulking and non-
debulking tumors, respectively; P = 0.001; Figure 2B).
To determine whether surgery alters proliferation in 
tumors, immunohistochemical staining was performed for 
the proliferation marker Ki67. The results demonstrated 
that debulking tumors exhibited an increased number 
of proliferating tumor cells relative to non-debulking 
tumors (80.3% vs 70.6%, debulking and non-debulking 
tumors, respectively; Figure 2C), and the difference in the 
percentage of Ki67 positive cells between the two groups 
was statistically significant (Figure 2D, P = 0.028, at least 
3 images were used per tumor). These results indicated 
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Figure 1: Survival in rats implanted with GBM is enhanced with surgical debulking. A. Representative images of implantation 
of spheroids with a wide bore syringe (1), burr hole drilled in the skull for implantation (2), craniectomy centered around the original burr 
hole in preparation for tumor debulking at week 4 (3), removal of skull bone (4), removal of tumor tissue by aspiration (5), and reinsertion 
of resected skull bone which was fixed with cyanoacrylate glue (6). B. Representative images of MRI and PET-CT scans of animals at one 
day before debulking (week 4), one day after debulking, and tumor recurrence (week 8). Circles (MRI) and arrows (PET) highlight areas 
of xenograft growth. C. Tumor volume (mm3) calculated from MRI scans plotted as a function of time in weeks. Tumor was resected at 
week 4 after implantation. D. Kaplan-Meier plots illustrating survival time (implantation = day 1) of nude rats (n = 6/group) with or without 
tumor debulking (P = 0.0005).
Figure 2: Increased proliferation index and vascular changes in debulking relative to non-debulking xenografts. 
Immunostaining performed on sections from debulking and non-debulking tumors (5 rats per group) with the antibodies indicated. 
A. vWF (magnification 20×) and B. quantification of the percentage of vessel area per view (P = 0.001); C. Ki67 (magnification 40×) and 
D. quantification of percentage of Ki-67 positive cells per view (P = 0.028). Scale bars = 100 μm.
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that surgery influenced the vessel morphology and the 
proliferation index in recurrent P3 GBM xenografts.
P3 GBM cells express CD47
The success of combination treatment including 
surgery and CD47 blocking immunotherapy is dependent on 
expression of CD47 in tumor cells. Human biopsy derived 
P3 GBM cells were therefore examined for expression 
of CD47 by immunocytochemistry and flow cytometry. 
Staining performed by immunocytochemistry demonstrated 
that CD47 was present on individual P3 GBM cells. The 
staining was specific as no positive signal was evident 
upon incubation of cells with only secondary antibody 
(Figure 3A). Analysis of CD47 expression was also 
performed with flow cytometry to confirm the results from 
immunocytochemistry and to examine the distribution of 
CD47 expression among P3 cells in single cell suspensions 
prepared from xenografts. The results confirmed that P3 
GBM cells expressed CD47, and furthermore demonstrated 
that P3 xenograft cells uniformly expressed the protein at 
high levels, as more than 98% of cells were found to be 
positive for CD47 (Figure 3B).
Anti-CD47 antibody promotes phagocytosis of 
GBM cells in vitro
To observe efficiency of engulfment of GBM cells 
by macrophages, P3 or P13 GBM cells were labeled with 
CFSE and subsequently incubated with PBS, IgG control 
antibody, or anti-CD47 monoclonal antibody in co-cultures 
with macrophages differentiated from nude rat bone 
marrow cells. After 2 h, co-cultures were imaged under 
fluorescence microscopy and fluorescent macrophages 
were counted (Figure 4A). Phagocytic indices indicated 
that P3 and P13 GBM cells incubated with anti-CD47 
antibody were more efficiently phagocytosed by rat 
macrophages than P3 and P13 cells treated with control 
IgG antibody or PBS (P3: 32%, 12% and 8%; and P13: 
82%, 42%, and 42%; CD47, IgG and PBS control, 
respectively; Figure 4B). Differences in uptake were 
statistically significant for anti-CD47 treated P3 and P13 
cells relative to the PBS and IgG antibody controls (P = 
0.00001 and 0.00008 for P3; P = 0.023 and = 0.015 for 
P13; PBS and IgG respectively). The results however also 
indicated that P3 cells treated with IgG alone were more 
efficiently engulfed by macrophages, 12% vs 8%, and this 
result was statistically significant (P = 0.00962).
Anti-CD47 antibody delays tumor growth of 
patient derived orthotopic GBM xenografts and 
prolongs the overall survival time in association 
with resection
Efficacy of treatment in animal models is more 
often assessed at an early stage in the development of 
xenografts, namely at implantation or shortly thereafter, 
Figure 3: P3 GBM cells uniformly express high levels of CD47. Cell suspensions were incubated with FITC-labeled anti-CD47 
antibody used for treatment in rats or IgG as a control. A. Fluorescent image of P3 tumor cells incubated with FITC-labeled anti-CD47 
antibody (green). DAPI (blue) was used for nuclear counterstaining. B. Analysis of CD47 expression by flow cytometry. Forward and side 
scatter plots of fixed cells, and percentage of cells FITC labeled (> 98%) in the gated population.
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which differs from the time of clinical intervention in 
GBM patients. In order to determine whether anti-CD47 
antibody was effective against tumor growth in a setting 
more similar to the clinic, treatment was initiated 4 weeks 
after implantation, a time point where tumor was clearly 
evident in rats by MRI (Figure 1B). Antibodies were 
injected directly into the tumor or resection-cavity in order 
to achieve a high local antibody concentration (Figure 5A), 
and MRI scanning was performed once a week to monitor 
tumor growth. Differences in tumor volumes evaluated by 
MRI scan were not evident in rats when treatment with anti-
CD47 was initiated at 4 weeks after implantation relative 
to controls (Figure 5B). Tumor volume as a function of 
time increased similarly for treatment with anti-CD47 or 
control IgG antibody, as for the control group, and anti-
CD47 treated animals became symptomatic within 6 weeks 
of implantation just as controls. Treatment with anti-CD47 
antibody thus did not inhibit tumor growth when injected at 
4 weeks after implantation into solid tumors.
When resection was performed in combination 
with initiation of anti-CD47 mAb treatment at 4 weeks, 
tumors still recurred in all cases (n = 6). The increase in 
tumor volume as observed on MRI scans however differed 
between groups (Figure 5B). Anti-CD47 mAb relative to 
IgG inhibited tumor growth in combination with resection, 
and differences in tumor volume compared to controls 
were statistically significant at weeks 7 (P = 0.0064), 8 (P 
= 0.0169) and 9 (P = 0.0062; Figure 5C).
Importantly, the observed delays in tumor growth in 
resected animals treated with anti-CD47 mAb treatment 
were associated with a significantly improved outcome 
compared to resected animals treated with IgG control 
antibody (81.5 days vs 69.0 days, anti-CD47 vs IgG 
control; P = 0.0007). However, survival times (~ 43 
days) remained unaffected in the non-debulking group 
regardless of treatment with anti-CD47 or IgG antibody 
(P = 0.443; Figure 5D).
Tumor debulking recruits M1 macrophages to 
the surgical site at the tumor edge
The improved efficacy of combination treatment 
might depend on the number and phenotype of 
macrophages/immune cells located within the tumor bed. 
To determine whether macrophages were recruited to the 
tumor-debulking site, staining for CD68 was first used as 
a general marker to identify immune cell types. Tumors 
from the debulking group exhibited a higher percentage of 
CD68+ cells (50% vs 10%, debulking and non-debulking, 
respectively). A distinct pattern of localization of 
macrophages was also apparent; macrophages surrounded 
and infiltrated the outer edge of the recurrent tumor 
(Figure 6A).
Macrophages have been functionally and 
molecularly characterized as tumor inhibiting (M1) or 
tumor promoting (M2). CD68 and pSTAT1 together 
are considered to be markers of M1 or activated 
macrophages while CD163 is more often associated 
with M2 macrophages. To determine the phenotype of 
macrophages in tumors, staining was performed for CD68, 
Figure 4: Nude rat bone marrow derived macrophages efficiently phagocytose P3 and P13 GBM tumor cells in an in 
vitro assay. A. Representative images of derived macrophages after incubation (2 h) with CFSE (green) labeled P3 and P13 tumor cells 
treated with anti-CD47 antibody or controls (PBS or IgG). Co-cultures were rinsed to remove free CFSE labeled P3 cells before imaging. 
B. Bar chart displaying the phagocytic index (number of phagocytosed tumor cells per 100 macrophages) with anti-CD47 antibody and 
controls (IgG and PBS) for two different GBM derived CD47+ xenografts, P3 and P13. Error bars represent SD.
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Figure 5: Local injection of anti-CD47 antibody inhibits tumor growth in combination with surgical debulking. A. 
View of local injection of anti-CD47 antibody through the opening used to implant spheroids. B. Representative images of final MRI scans 
before sacrifice. C. Tumor volume derived from MRI scans and plotted as a function of time in weeks from rats treated with anti-CD47 or 
IgG antibodies with or without debulking. D. Survival of nude rats with GBM xenografts treated with anti-CD47 or IgG antibodies with 
or without debulking.
Figure 6: Macrophages coexpressing M1 (pSTAT1 and CD68) and M2 (CD163) polarization related markers are 
recruited to debulking xenografts. Immunostaining performed on sections from xenografts as indicated for A. CD68; B. pSTAT1; 
C. CD68 and pSTAT1; and D. CD163. E. Quantification of macrophages based on percentage of CD68 positive cells per view (P = 0.021). 
F. Quantification of macrophages based on percentage of CD163 positive cells per view (P = 0.003). Scale bar = 100μm.
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pSTAT1, CD68 + pSTAT1 and CD163 (Figure 6B – 
6D). CD68+/pSTAT1+ double positive cells were found 
in the tumor debulking group whereas no pSTAT1+ cells 
were observed in the non-debulking group (Figure 6C). 
Tumors from the debulking group also exhibited a higher 
percentage of CD163+ cells (36.5% vs 7.5%, debulking 
and non-debulking, respectively). The localization of 
these M2 macrophages was similar to M1 macrophages; 
CD163+ also surrounded and infiltrated the outer edge of 
the recurrent tumor (Figure 6D). Quantification of the 
percentage of CD68+ cells (Figure 6E) and CD163+ cells 
(Figure 6F) per image revealed a statistically significant 
difference between the two groups. These results indicated 
that recruitment of both M1 and M2 macrophages was 
associated with tumor resection. Therefore, either type 
might promote the delay in tumor growth stimulated by 
tumor resection alone or in combination with anti-CD47 
treatment.
Protein expression profiles correlate with an 
enhanced inflammatory cytokine profile and 
decreased angiogenesis in debulking anti-CD47 
treated xenografts
To unravel the molecular mechanisms underlying 
the combined treatment effect, expression of cytokines 
and angiogenesis-associated proteins in tumor tissue 
from debulking+IgG and debulking+CD47 groups was 
evaluated on antibody protein capture microarrays. 
Debulking xenografts treated with CD47 antibody were 
characterized by significantly higher expression of 
cytokines/chemokines and immune cell markers CINC-
3, CD54, IL-1F3, CXCL10, CXCL9, and CCL5 relative 
to debulking tumors treated with IgG antibody therapy 
(P < 0.05; Figure 7A). Quantification of angiogenesis 
associated proteins revealed that AR, CXCL16, GDNF, 
GM-CSF, CCL3, PDGF-AA, PIGF, Serpin B5, TIMP4 
Tsp2 and VEGF-C were downregulated while Serpin E1 
was upregulated in debulking tumors treated with anti-
CD47 compared to debulking tumors treated with IgG (P 
< 0.05; Figure 7B). These results indicated that resection 
of xenografts combined with anti-CD47 treatment was 
associated with an enhanced inflammatory cytokine profile 
and a decrease in angiogenesis.
DISCUSSION
GBM patients typically undergo surgical resection 
followed by chemo-/radiation therapy, but they inevitably 
experience relapse. At present, few animal models exist 
that precisely mimic this clinical course for GBM patients. 
Although surgical resection of GBM in mouse models 
has been previously reported, xenografts were initiated 
with glioma cell lines that do not accurately represent 
GBM in patients. Furthermore, the cranial window in 
the animal was either reconstructed with titanium mesh 
or not repaired [24–27]. Here, we developed a protocol 
for a novel xenograft surgical resection and tumor relapse 
model using patient derived spheroids. The model was 
subsequently used to examine the clinical benefits of 
surgery combined with a novel immunotherapy. The 
results demonstrated first that debulking enhanced 
survival in animals, and reflected the therapeutic benefit 
of surgical resection in patients [5, 12, 28–31]. In 
addition, increases in proliferation and in dilated tumor 
vessels (vWf) in relapsed tumor recapitulated pathological 
Figure 7: Anti-CD47 antibody treatment alters levels of cytokines and angiogenesis-associated proteins in GBM 
xenografts. Protein arrays for A. cytokines and B. angiogenesis-associated proteins were incubated with protein lysates (400 μg) prepared 
from debulking tumor tissue treated with IgG or anti-CD47 as indicated. Data shown represent a 1000 s exposure to X-ray film.
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characteristics of recurrent human GBMs which display 
both angiogenic and invasive phenotypes [32]. Second, 
anti-CD47 treatment enhanced antitumor activity but only 
in combination with surgery. Finally, molecular expression 
paralleled pathological findings in tumors. These results 
support our model for further investigation particularly 
in combination therapy as well as provided potential 
mechanisms for the efficacy of surgery combined with 
anti-CD47 therapy.
A potential mechanism underlying therapeutic 
enhancement with anti-CD47 antibody may be the 
increased number/density of double positive pSTAT1-
CD68 macrophages found in recurrent GBM tissue 
relative to non-resected xenografts. These results indicated 
that an increased number of macrophages, specifically 
activated macrophages, had been recruited to the tumor 
debulking site. Previous studies have demonstrated that 
activated macrophages in glioma tissue express high levels 
of CD163, CD68, CD206, and CD204 [33–36]. CD68 
was used as a marker of tumor associated macrophages 
(TAMs) in most papers included in a meta-analysis [37] 
and was highly expressed on both M1 (tumor inhibiting) 
and M2 (tumor promoting) macrophages [38]. CD163 
however was found to be expressed in M2 macrophages 
and has been used to distinguish between M1 and M2 cell 
types [39, 40]. To date, it remains difficult to differentiate 
between M1 and M2 TAM phenotypes in GBM. However, 
one study has suggested that M1 macrophages can be 
identified by simultaneous expression of CD68 and 
pSTAT1 [41]. If these markers are indeed consistent with 
an activated macrophage phenotype, our study is the first 
to illustrate their increased presence in resected GBM 
tumors.
The protein profiles extracted from the arrays were 
also consistent with more efficient recruitment of TAMs 
to debulking + CD47 tumors. TAMs have been shown 
to be recruited into tissues from the circulation by CCL5 
[42, 43] which might also be expressed by macrophages 
[43]. In addition, activated macrophages are the cells 
that secrete most chemokines, including CXCL9 and 
CXCL10, into the tumor environment [44–47]. These 
cytokines were all found to be significantly upregulated 
in the debulking tumor + CD47 antibody group and 
may therefore provide a molecular explanation for the 
increased infiltration of macrophages into recurrent 
tumor as well as antibody stimulated antitumor activity 
in these macrophages. CINC-3 is a strong chemotactic 
factor for neutrophils and was found to be downregulated 
in the debulking tumor + CD47 antibody group. The 
biological effect of decreased CINC-3 on tumor growth 
is unclear and should be investigated in future studies. 
CD54 (ICAM-1) is a member of the immunoglobulin 
superfamily and is expressed on endothelial cells, 
epithelial cells, and fibroblasts, as well as T-cells, B-cells, 
dendritic cells, macrophages, and eosinophils [48]. Studies 
have demonstrated that CD54 plays an important role in 
facilitating tumor invasion and metastases [49, 50]. In our 
study, CD54 was found to be significantly upregulated in 
the debulking tumor + CD47 antibody group. Increased 
expression may be due to an increase in the number of 
macrophages recruited to recurrent tumor. The result was 
consistent with a study showing that CD47 blockade leads 
to increased macrophage infiltration in tumors [51]. In 
addition, angiogenesis-promoting proteins, such as AR, 
CXCL16, GDNF, GM-CSF, CCL3, PDGF-AA, PIGF, are 
downregulated. These results provide a molecular basis 
for why combination therapy led to significantly slower 
growth than in controls. Thus, all together, these results 
provide a potential mechanism for the enhanced anti-
tumor activity observed with blockade of CD47-SIRPa in 
the context of surgical debulking.
Our observation that anti-CD47 therapy had no 
effect on the primary tumor mass in nude rats in the 
absence of debulking, corroborates previous results. In a 
previous study, anti-CD47 antibody elicited a profound 
effect in the treatment of solid tumors including GBM; 
however, efficacy of anti-CD47 blockade was highly 
correlated with tumor size [23]. This result was surprising 
as our in vitro experiments had shown significant 
phagocytosis of tumor cells in the anti-CD47 group, but 
it was only smaller size after debulking in rats in the 
anti-CD47 group that was associated with significantly 
longer survival compared to controls. The results indicate 
that anti-CD47 therapy effectively enhanced treatment 
of recurrent tumors in the context of postsurgical tumor 
resection and thus might potentially improve overall 
survival of patients with GBM.
One of the potential drawbacks of anti-CD47 therapy 
is the method of delivery. Rats had also been treated with 
anti-CD47 antibody by tail vein injection, but no efficacy 
was observed (data not shown). The reasons for failure 
of the treatment administered by this method may be the 
inability of antibody to cross the blood–brain tumor barrier 
and/or an insufficient antibody concentration for the 
inhibition of tumor growth in the rat GBM model. Other 
treatment options such as temozolomide, the angiogenesis 
inhibitor endostatin or encapsulated therapeutic stem cells 
have exhibited efficacy when locally administered in 
animal models [25, 26, 52]. Therefore, anti-CD47 therapy 
was administered by local injection immediately following 
debulking of tumors. Local delivery or alternative delivery 
strategies should, thus, be considered over systemic 
delivery methods when administering antibody therapy in 
clinical trials with brain tumors.
In conclusion, CD47 was found to be highly 
and uniformly expressed on P3 patient derived GBM 
cells. Inhibiting CD47 with anti-CD47 mAbs enabled 
phagocytosis of GBM cells by macrophages in vitro, 
and postsurgical treatment by local injection of anti-
CD47 serves as an effective method in vivo. These results 
support the rationale for evaluating clinical efficacy of 
anti-CD47 therapy post-surgically in human patients with 
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GBM. In addition, the statistically significant enhancement 
of survival in combination treatment of recurrent tumor 
is possibly driven by recruitment of CD68+/pSTAT1+ 
macrophages and inhibition of angiogenesis. Additional 
studies are necessary to address the relationship between 
efficacy of anti-CD47 treatment and the density of TAMs 
in human GBMs, and the feasibility of combining CD47 
blocking immunotherapy with cytokines that modulate 




The collection of human biopsy tissue for research 
purposes was approved by the Regional Ethical Committee 
(REK Vest, project number 013.09; Bergen, Norway), 
and written informed consent was obtained from patients 
before surgery. All procedures and experiments involving 
animals in this study were approved by the National 
Animal Research Authority (Norway) and conducted 
according to the European Convention for the Protection 
of Vertebrates Used for Scientific Purposes.
Preparation of patient GBM-derived spheroids
Patient GBM-derived spheroids (P3, P13) were 
originally generated in vitro in our laboratory from primary 
tumor tissue as previously described [32]. Spheroids 
were subsequently implanted into nude rat brains in 
order to establish clinically and biologically relevant 
GBM xenografts. Xenografts have been maintained 
and expanded through serial passage in animals with 
the generation of spheres in vitro before the subsequent 
implantation in vivo. Implantations for tumor debulking 
experiments were standardized through the selection of a 
pool of in vitro generated spheres (n = 5; 300 – 400 μm in 
diameter) which developed into phenotypically identical 
xenografts (angiogenic and invasive) within the expected 
timeframe of ~ 30 days in nude rats.
Spheroid implantation
Immunocompromised athymic nude rats (rnu -/-) 
were used for all implantations. These animals have been 
previously shown to be a favorable host for serial passage 
of human GBM xenografts, and their size makes them 
amenable to experimental procedures including surgeries 
and MRI and PET scans. For implantations, rats were 
anesthetized (3.5 mL/kg) with a mixture of Fentanyl (10 
mL at 50 mg/mL; Hameln Pharma; Halmeln; Germany) 
and Domitor (1 mL at 1 mg/mL; Orion Pharma; Espoo, 
Finland), and fixed in a stereotactic frame (Benchmark; 
Neurolab, St Louis, MO). A small hole was made in the 
skull with a bit (2.9 mm in diameter), and human GBM 
spheroids (n = 5) were slowly injected through a wide 
bore Hamilton syringe (Hamilton; Reno, NV, USA) into 
the brain of athymic nude rats (n = 40; Figure 3A) at the 
following coordinates: 1 mm posterior to the bregma and 
3 mm to the right of the midline suture at a depth of 2.5 
mm. The incision was closed with 4/0 interrupted simple 
sutures and cleaned with alcohol.
MRI and PET-CT scanning
MRI was performed on a 7T Pharmascan (Bruker; 
Ettlingen, Germany). Sequence details have been described 
previously [53]. Brain MRI was performed to evaluate 
tumor growth with pre-/post-contrast T1-weighted 
sequences. PET-CT scans were performed using a nanoScan 
PC PET/CT (Mediso Medical Imaging Systems Ltd, 
Budapest, Hungary) with F18-FET performed through tail 
vein injection with a dose of 15 MBq per rat.
Surgical tumor debulking
Tumor growth in nude rats was monitored by MRI 
scan, and determined to be sufficient at ~ 4 weeks after 
implantation for debulking and antibody experiments. 
Animals were anesthetized and fixed in the stereotactic 
frame as for implantations, and respiration was closely 
monitored. The previous incision was extended, and 
surgical retractors were used to open the surgical field. 
The previous burr hole used for spheroid implantation 
was identified. A craniotomy (5 mm in diameter) was 
centered on the previously made burr-hole using a high-
speed dental drill (diameter of 0.5 mm) under a dissecting 
microscope. Tumor was exposed with a durotomy and 
gently dissected as much as possible along the interface 
between tumor and normal brain tissue with a dissecting 
microscope or an aspirator. Hemostasis was achieved 
with a hand-held electrocautery pen with a fine needle 
tip, and the surgical cavity was rinsed with sterile saline. 
The resected skull bone was reinserted after the resection 
and fixed with cyanoacrylate glue. The incision was 
closed with 4/0 interrupted simple sutures and cleaned 
with alcohol; antibiotics however were not administered. 
Resected animals underwent immediate post-operative 
MRI scanning and were returned to their cages when fully 
recovered. Animals were closely monitored thereafter 
for neurological deficits such as seizures, paresis, and 
significant weight loss.
Histopathology, immunohistochemistry and 
quantitative analysis
Brains were fixed in 4% formalin, embedded 
in paraffin, and sectioned (5 μm). Sections were 
stained with hematoxylin and eosin, and examined 
by a neuropathologist under a light microscope. 
For immunohistochemical analysis, sections were 
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deparaffinized and rehydrated, and pretreated for 25 min 
in citrate buffer (pH 6.0) at 100°C followed by cooling for 
50 min at 4°C in a refrigerator. Endogenous peroxidase 
was quenched with a 5 min incubation in Peroxidase 
Blocking Solution (K4007; DAKO; Glostrup; Denmark). 
Sections were blocked with DAKO Protein Block 
(X0909; DAKO) for 30 min and incubated overnight 
at 4°C with primary antibody. The antibodies used 
were the following: Ki67 (1:75, MIB-1 clone, DAKO); 
von Willebrand Factor (1:500, DAKO); CD68 (1:100, 
ab31630, Abcam; Cambridge, MA, USA); p-STAT1 
(1:300, Tyr701, Santa Cruz Biotechnology; Dallas, 
TX, USA); and CD163 (1:100, Serotec; Oxford, UK). 
Detection was performed using biotinylated secondary 
antibody conjugated to peroxidase (40 min incubation; 
anti-mouse, K4007; anti-rabbit, K4011; DAKO) 
and DAB+ as the substrate (3 min; K4007; DAKO) 
according to the manufacturer’s instructions. Sections 
were counterstained with hematoxylin, dehydrated and 
mounted in Entellan (Merck; Darmstadt, Germany). 
Histological analysis was performed using a Nikon 
Eclipse E600 light microscope (Nikon; Tokyo, Japan). 
Quantification of Ki67, von Willebrand Factor (vWF), 
CD68 and pSTAT1 (5 tumors per experimental group, 3 
different areas per tumor) was performed with the imaging 
software NIS-Elements BR 4.11.00 64-bit (Nikon). The 
number of Ki67 and vWF positively stained cells were 
counted in 9 non-overlapping randomly selected areas (at 
400× magnification) from at least three different tumor-
bearing brains from each group.
Single cell suspensions
Single cell suspensions were prepared by incubating 
P3 and P13 xenograft material with trypsin-EDTA 
(Lonza Ltd.; Basel, Switzerland) for 10 min in a shaking 
water bath at 37°C, followed by gentle trituration with 
a 1000 µl pipette tip. Cells were subsequently used for 
immunocytochemistry and flow cytometry or labeled with 
5 µM carboxyfluorescein succinimidyl ester (CFSE) for in 
vitro phagocytosis assays.
Immunocytochemistry (ICC) and flow cytometry
For ICC, single cells were seeded onto coverslips 
in a 24-well plate, allowed to attach overnight, rinsed 
twice with phosphate-buffered saline (PBS; Dulbecco’s 
phosphate-buffered saline; Sigma-Aldrich; St. Louis, 
MO, USA), fixed for 10 min in 4% paraformaldehyde 
(PFA, Thermo Scientific, Rockford, USA), and rinsed 
three times with PBS. Coverslips were blocked in 0.5 
% bovine serum albumin blocking buffer for 15 min, 
incubated with primary anti-CD47 antibody (BioXCell; 
Beverly, MA, USA) for 45 min at 37°C, rinsed twice with 
PBS, incubated with FITC-conjugated secondary anti-
mouse antibody (1:200; Southern Biotech; Birmingham, 
Alabama, USA) for 45 min at 37°C, rinsed twice in PBS, 
and mounted in Vectashield mounting medium (Vector 
Laboratories; Burlingame, California, USA) with DAPI. 
Coverslips were imaged with fluorescence microscopy 
(Nikon TE2000 microscope; Nikon; Tokyo, Japan). 
Cells stained with secondary antibody only were used as 
the control. For flow cytometry, single cell suspensions 
were immediately fixed in 4% PFA for 10 min followed 
by a wash with PBS, 15 min blocking in 0.5% BSA, and 
incubation with anti-CD47 or isotype control antibody 
for 20 min at room temperature. CD47 staining was 
acquired on an AccuriC6 instrument (Becton Dickinson; 
Erembodegem, Belguim), and analyzed in FlowJo 
(TreeStar Inc.; Ashland, Oregon, USA). Positive gates 
were set on the basis of the isotype control staining.
In vitro phagocytosis assay
Macrophages for in vitro experiments were 
differentiated from bone marrow cells harvested from 
femurs of athymic nude rats (HsdHan™: rnu/rnu 
Rowett). Femurs were collected from rats sacrificed by 
CO2 inhalation and dislocation of the neck, and attached 
tissue was removed. Both ends of each femur were cut 
with sterile scissors, and the bone marrow was flushed 
out into a 70 µm cell strainer in a petri dish with sterile 
PBS expelled from a syringe with a 22-gauge needle. 
Red blood cells were lysed with Red Blood Cell Lysing 
buffer (Sigma-Aldrich) according to the manufacturer’s 
protocol. Bone marrow cells were suspended in 
Dulbecco's Modified Eagle Medium (DMEM, Sigma-
Aldrich) supplemented with 10 ng/mL granulocyte-
macrophage colony-stimulating factor (GM-CSF; 
Peprotech; Rocky Hill, NJ, USA), 10% fetal bovine 
serum, non-essential amino acids, 100 U/mL Pen/Strep 
and 400 μM L-glutamine (Cambrex; East Rutherford, 
NJ, USA), and cultured for 6 days in non-tissue culture 
treated 10 cm dishes (BD Biosciences; Franklin Lakes, 
NJ, USA). Differentiated macrophages were detached in 
10 mM ethylenediaminetetraacetic acid (EDTA; Merck) 
using a cell scraper and viable macrophages (50,000/
well) were seeded into the wells of a 24-well plate. After 
culture overnight, complete DMEM was replaced with 
serum-free DMEM 2 h before introducing CFSE labeled 
P3 or P13 GBM cells (n = 200,000) to the macrophages 
(n = 50,000). This ratio of tumor cells to macrophages 
in vitro roughly mimics the situation in vivo, i.e. number 
of tumor cells is > the number of macrophages. After a 
2 h incubation at 37°C, the anti-human CD47 or IgG1 
antibody (10 μg/mL) and PBS as control were added to the 
co-cultures, and imaging was performed after rinsing wells 
four times with PBS (1 mL) to remove non-phagocytosed 
P3 and P13 GBM cells. All co-culture experiments were 
performed three times with at least three parallels, and 
random images were taken from each of the parallels for 
each condition. The phagocytic index was calculated by 
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counting the number of phagocytosed tumor cells per 100 
macrophages in 3x3 images for each condition.
Antibody treatment
Four weeks after spheroid implantation, the animals 
were grouped into the following six different experimental 
groups: tumor non-debulking (n = 6); tumor non-
debulking with IgG isotype control treatment (MOPC-
21; BioXCell; n = 6); tumor non-debulking with anti-
human CD47 antibody treatment (B6.H12; BioXCell; n 
= 6); tumor debulking (n = 6); tumor debulking combined 
with IgG isotype control treatment (n = 6); and tumor 
debulking combined with anti-human CD47 antibody 
treatment (n = 6). The two antibodies were resolubilized 
in 1×PBS at a concentration of 5 mg/mL, and 50 µL were 
administered once every two days by local injection 
through the implantation burr hole starting from 4 weeks 
post-implantation and continuing until the experiment was 
terminated. Rats underwent MRI imaging (w/wo contrast) 
weekly to monitor tumor growth. Rats were sacrificed 
when neurological deficits such as seizures, paresis, 
and significant weight loss had occurred. Tumors were 
removed and either formalin fixed for histology or snap 
frozen in liquid N2 for protein extraction.
Cytokine and human angiogenesis antibody 
protein capture microarrays
Protein lysates were prepared from snap frozen 
xenografts, and proteins (400 μg) were incubated with 
the Rat Cytokine Array Kit, Panel A, and the Human 
Angiogenesis Array Kit (R&D Systems; Minneapolis, 
MN, USA) according to the manufacturer’s instructions. 
Collection and quantification of pixel densities from 
membranes was performed using the Fuji Las3000 
(Fujifilm; Tokyo, Japan) and Image Reader LAS-3000 
(Version 2.2; Fujifilm). Arrays for all samples were 
performed in duplicate, and an average density was 
calculated for each corresponding protein probed on the 
arrays based on the two pixel densities determined for 
each experiment.
Statistical analysis
Brain MRI was performed to evaluate tumor 
growth and the tumor volume was evaluated with OsiriX 
5.8.2. Survival was analyzed by a log-rank test based on 
the Kaplan-Meier test using Graphpad Prism software. 
Differences between pairs of groups were determined by 
the unpaired 2-tailed Student’s t-test. P-values < 0.05 were 
considered significant.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
GRANT SUPPORT
This work was supported by the Special Foundation 
for Taishan Scholars (ts20110814 and tshw201502056), 
the Fundamental Research Funds of Shandong University, 
the Department of Science & Technology of Shandong 
Province (2015GGE27101 and 2015ZDXX0801A01), 
the University of Bergen, Helse Bergen, Norway, the 
Stiftelsen Kristian Gerhard Jebsen, the Norwegian Cancr 
Society and the Norwegian Centre for International 
Cooperation in Education (SIU)(UTF-2014/10047).
REFERENCES
1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn 
MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger 
K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, 
Mokhtari K, et al. Effects of radiotherapy with concomitant 
and adjuvant temozolomide versus radiotherapy alone on 
survival in glioblastoma in a randomised phase III study: 
5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 
2009; 10:459-466.
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi 
M, Weller M, Stupp R. Current concepts and management 
of glioblastoma. Ann Neurol. 2011; 70:9-21.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher 
B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, 
Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, 
Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. 
N Engl J Med. 2005; 352:987-996.
4. Laws ER, Parney IF, Huang W, Anderson F, Morris 
AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan 
A, Berger MS, Chang S, Glioma Outcomes I. Survival 
following surgery and prognostic factors for recently 
diagnosed malignant glioma: data from the Glioma 
Outcomes Project. J Neurosurg. 2003; 99:467-473.
5. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi 
W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch 
SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. 
A multivariate analysis of 416 patients with glioblastoma 
multiforme: prognosis, extent of resection, and survival. J 
Neurosurg. 2001; 95:190-198.
6. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, 
Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski 
B, Woiciechowsky C, Franz K, Pietsch T, Group AL-GS. 
Extent of resection and survival in glioblastoma multiforme: 
identification of and adjustment for bias. Neurosurgery. 
2008; 62:564-576; discussion 564-576.
7. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, 
Weller M, Cairncross JG, Eisenhauer E, Belanger K, 
Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms 
for predicting survival of patients with newly diagnosed 
glioblastoma: prognostic factor analysis of EORTC and 
NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008; 
9:29-38.
Oncotarget12156www.impactjournals.com/oncotarget
8. Brennan C, Momota H, Hambardzumyan D, Ozawa T, 
Tandon A, Pedraza A, Holland E. Glioblastoma subclasses 
can be defined by activity among signal transduction 
pathways and associated genomic alterations. PLoS One. 
2009; 4:e7752.
9. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano 
RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu 
L, Williams PM, Modrusan Z, Feuerstein BG, Aldape 
K. Molecular subclasses of high-grade glioma predict 
prognosis, delineate a pattern of disease progression, 
and resemble stages in neurogenesis. Cancer Cell. 2006; 
9:157-173.
10. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins 
VP, Marioni JC, Curtis C, Watts C, Tavare S. Intratumor 
heterogeneity in human glioblastoma reflects cancer 
evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 
110:4009-4014.
11. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, 
Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza 
RL, Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, 
Bernstein BE. Single-cell RNA-seq highlights intratumoral 
heterogeneity in primary glioblastoma. Science. 2014; 
344:1396-1401.
12. Stummer W, van den Bent MJ, Westphal M. Cytoreductive 
surgery of glioblastoma as the key to successful adjuvant 
therapies: new arguments in an old discussion. Acta 
Neurochir (Wien). 2011; 153:1211-1218.
13. Koritzinsky M, Seigneuric R, Magagnin MG, van den 
Beucken T, Lambin P, Wouters BG. The hypoxic proteome 
is influenced by gene-specific changes in mRNA translation. 
Radiother Oncol. 2005; 76:177-186.
14. Brzozowska A, Torun A, Mazurkiewicz M. The impact of 
surgery on the efficacy of adjuvant therapy in glioblastoma 
multiforme. Adv Clin Exp Med. 2015; 24:279-287.
15. Brown EJ, Frazier WA. Integrin-associated protein (CD47) 
and its ligands. Trends Cell Biol. 2001; 11:130-135.
16. Jiang P, Lagenaur CF, Narayanan V. Integrin-associated 
protein is a ligand for the P84 neural adhesion molecule. J 
Biol Chem. 1999; 274:559-562.
17. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, 
Gresham HD, Lindberg FP. Role of CD47 as a marker of 
self on red blood cells. Science. 2000; 288:2051-2054.
18. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, 
Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 
is upregulated on circulating hematopoietic stem cells 
and leukemia cells to avoid phagocytosis. Cell. 2009; 
138:271-285.
19. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, 
Gibbs KD, Jr., van Rooijen N, Weissman IL. CD47 is an 
adverse prognostic factor and therapeutic antibody target 
on human acute myeloid leukemia stem cells. Cell. 2009; 
138:286-299.
20. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese 
B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao 
F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, et al. 
Anti-CD47 antibody synergizes with rituximab to promote 
phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 
2010; 142:699-713.
21. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh 
AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, 
Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin 
is the dominant pro-phagocytic signal on multiple human 
cancers and is counterbalanced by CD47. Sci Transl Med. 
2010; 2:63ra94.
22. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-
Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti 
R. Therapeutic antibody targeting of CD47 eliminates 
human acute lymphoblastic leukemia. Cancer Res. 2011; 
71:1374-1384.
23. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba 
P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen 
JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, 
Tang C, Volkmer AK, et al. The CD47-signal regulatory 
protein alpha (SIRPa) interaction is a therapeutic target 
for human solid tumors. Proc Natl Acad Sci U S A. 2012; 
109:6662-6667.
24. Hingtgen S, Figueiredo JL, Farrar C, Duebgen M, Martinez-
Quintanilla J, Bhere D, Shah K. Real-time multi-modality 
imaging of glioblastoma tumor resection and recurrence. J 
Neurooncol. 2013; 111:153-161.
25. Akbar U, Jones T, Winestone J, Michael M, Shukla A, 
Sun Y, Duntsch C. Delivery of temozolomide to the tumor 
bed via biodegradable gel matrices in a novel model of 
intracranial glioma with resection. J Neurooncol. 2009; 
94:203-212.
26. Kauer TM, Figueiredo JL, Hingtgen S, Shah K. 
Encapsulated therapeutic stem cells implanted in the tumor 
resection cavity induce cell death in gliomas. Nat Neurosci. 
2012; 15:197-204.
27. Bello L, Giussani C, Carrabba G, Pluderi M, Lucini V, 
Pannacci M, Caronzolo D, Tomei G, Villani R, Scaglione 
F, Carroll RS, Bikfalvi A. Suppression of malignant 
glioma recurrence in a newly developed animal model 
by endogenous inhibitors. Clin Cancer Res. 2002; 
8:3539-3548.
28. Garcia-Corrochano P, Castaneda CA, Orrego E, Deza P, 
Heinicke H, Casavilca S, Castillo M, Cortez K, Belmar 
C, Dolores K, Flores C, Ojeda L. Microsurgical resection 
of glioblastoma guided with intraoperative fluorescein: a 
Retrospective evaluation. [Article in Spanish]. Rev Peru 
Med Exp Salud Publica. 2015; 32:471-478.
29. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger 
MS. An extent of resection threshold for newly diagnosed 
glioblastomas. J Neurosurg. 2011; 115:3-8.
30. Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott 
MW, Berger MS, Parsa AT. Impact of extent of resection for 
recurrent glioblastoma on overall survival: clinical article. J 
Neurosurg. 2012; 117:1032-1038.
Oncotarget12157www.impactjournals.com/oncotarget
31. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, 
Sabel M. Glioblastoma multiforme of the elderly: the 
prognostic effect of resection on survival. J Neurooncol. 
2011; 103:611-618.
32. Wang J, Miletic H, Sakariassen PO, Huszthy PC, Jacobsen 
H, Brekka N, Li X, Zhao P, Mork S, Chekenya M, 
Bjerkvig R, Enger PO. A reproducible brain tumour model 
established from human glioblastoma biopsies. BMC 
Cancer. 2009; 9:465.
33. Glass R, Synowitz M. CNS macrophages and peripheral 
myeloid cells in brain tumours. Acta Neuropathol. 2014; 
128:347-362.
34. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, 
Ito Y, Inamura T, Ikezaki K, Fukui M, Iwaki T, Kuwano M. 
Macrophage infiltration and heme oxygenase-1 expression 
correlate with angiogenesis in human gliomas. Clin Cancer 
Res. 1999; 5:1107-1113.
35. Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, 
Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, 
Cotzia P, Hooper DC. Glioma grade is associated with the 
accumulation and activity of cells bearing M2 monocyte 
markers. Clin Cancer Res. 2013; 19:3776-3786.
36. Li W, Graeber MB. The molecular profile of microglia 
under the influence of glioma. Neuro Oncol. 2012; 
14:958-978.
37. Bingle L, Brown NJ, Lewis CE. The role of tumour-
associated macrophages in tumour progression: implications 
for new anticancer therapies. J Pathol. 2002; 196:254-265.
38. Holness CL, Simmons DL. Molecular cloning of CD68, 
a human macrophage marker related to lysosomal 
glycoproteins. Blood. 1993; 81:1607-1613.
39. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 
Macrophage polarization: tumor-associated macrophages 
as a paradigm for polarized M2 mononuclear phagocytes. 
Trends Immunol. 2002; 23:549-555.
40. Gordon S. Alternative activation of macrophages. Nat Rev 
Immunol. 2003; 3:23-35.
41. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek 
G. Macrophage polarisation: an immunohistochemical 
approach for identifying M1 and M2 macrophages. PLoS 
One. 2013; 8:e80908.
42. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima 
T, Miyazaki M, Ochiai A. Stromal MCP-1 in mammary 
tumors induces tumor-associated macrophage infiltration 
and contributes to tumor progression. Int J Cancer. 2009; 
125:1276-1284.
43. Soria G, Ben-Baruch A. The inflammatory chemokines 
CCL2 and CCL5 in breast cancer. Cancer Lett. 2008; 
267:271-285.
44. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali 
L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine 
receptor specific for IP10 and mig: structure, function, and 
expression in activated T-lymphocytes. J Exp Med. 1996; 
184:963-969.
45. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker 
E, Gillitzer R. Strong expression of the lymphoattractant 
C-X-C chemokine Mig is associated with heavy infiltration 
of T cells in human malignant melanoma. J Pathol. 1999; 
189:552-558.
46. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame 
C, Francalanci M, Uguccioni M, Galli G, Cosmi L, 
Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio 
M. Cell cycle-dependent expression of CXC chemokine 
receptor 3 by endothelial cells mediates angiostatic activity. 
J Clin Invest. 2001; 107:53-63.
47. Payne AS, Cornelius LA. The role of chemokines in 
melanoma tumor growth and metastasis. J Invest Dermatol. 
2002; 118:915-922.
48. Stanciu LA, Djukanovic R. The role of ICAM-1 on 
T-cells in the pathogenesis of asthma. Eur Respir J. 1998; 
11:949-957.
49. Frenette PS, Wagner DD. Adhesion molecules--Part 1. N 
Engl J Med. 1996; 334:1526-1529.
50. O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone 
C, Given HF. Soluble adhesion molecules (E-selectin, 
ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer. 
2002; 38:2252-2257.
51. Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin 
S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya 
GA, Mohanakumar T, Frazier WA, Lin Y, Chapman WC. 
Antibody mediated therapy targeting CD47 inhibits tumor 
progression of hepatocellular carcinoma. Cancer Lett. 2015; 
360:302-309.
52. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn 
IF, Abe T, Carroll RS, Black PM. Continuous release of 
endostatin from microencapsulated engineered cells for 
tumor therapy. Nat Biotechnol. 2001; 19:35-39.
53. Sundstrom T, Daphu I, Wendelbo I, Hodneland E, 
Lundervold A, Immervoll H, Skaftnesmo KO, Babic M, 
Jendelova P, Sykova E, Lund-Johansen M, Bjerkvig R, 
Thorsen F. Automated tracking of nanoparticle-labeled 
melanoma cells improves the predictive power of a brain 
metastasis model. Cancer Res. 2013; 73:2445-2456.
